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Distinctive molecular characteristics of functionally diverse lymphocyte populations may 
represent novel pharmacological targets for immunotherapy. The intrinsic apoptosis 
pathway is differently regulated among conventional and regulatory T cells (Tregs). 
Targeted pharmacological modulation of this pathway with a small molecule Bcl-2/
Bcl-xL inhibitor (ABT-737) caused a selective depletion of effector T cells and a relative 
enrichment of Tregs in  vivo. Treatment with ABT-737 resulted in a tolerogenic milieu, 
which was exploited to alleviate graft-versus-host disease, to prevent allograft rejection 
in a stringent fully MHC-mismatched skin transplantation model and to induce immuno-
logical tolerance in combination with bone marrow transplantation. This concept has the 
potential to find various applications for immunotherapy, since it allows pharmacologic 
exploitation of the immunomodulatory properties of Tregs without the need for cell 
manipulation ex vivo.
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inTrODUcTiOn
Maintenance of immunological tolerance requires functional CD4+CD25+FoxP3+ regulatory T cells 
(Tregs). Lack of Tregs results in fatal autoimmune lymphoproliferative disorder in mice and IPEX 
syndrome in humans (1, 2). The immunomodulatory potency of Tregs attracted great interest for 
immunotherapy in autoimmunity, allergy, and transplantation (3). The promising results obtained 
by adoptive transfer of Tregs in experimental models are currently being translated into clinical 
pilot studies of type 1 diabetes, graft-versus-host disease (GVHD), and solid organ transplantation 
(4, 5). However, individualized cell therapy requires specific infrastructure for Treg isolation and 
expansion, bears high costs and potential risks regarding stability, homogeneity, and fate of trans-
ferred Tregs (6–8). The growing understanding of the physiological mechanisms determining Treg 
development and survival might lead to alternative strategies to exploit their immunomodulatory 
properties directly in vivo.
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Apoptosis is instrumental in shaping the immune cell rep-
ertoire and maintaining immune homeostasis. Pore formation 
in the mitochondrial outer membrane by Bax/Bak initiates an 
orchestrated dismantling of the cell by caspases (9). As pore 
formation is the point-of-no-return leading ultimately to cell 
death, this process has to be tightly regulated. Diverse internal 
and external signals, such as cytokine availability, T cell receptor 
(TCR) engagement, or costimulation, regulate the expression 
of pro- and antiapoptotic Bcl-2 family proteins in lymphocytes 
and thereby control the fate of the cell (10). Hence, the intrinsic 
apoptosis pathway is critically involved in controlling deletional 
tolerance in the thymus (11–13), selection of high-affinity clones 
(14), contraction of the conventional T cell (Tcon) pool after anti-
genic clearance (15), and maintenance of long-lived memory T 
cells (16). Importantly, survival of distinct T cell subpopulations 
depends on different Bcl-2 proteins. Naïve effector and memory T 
cells depend on Bcl-2 expression (16, 17), whereas IL-2-regulated 
Mcl-1 expression is particularly important for Treg homeostasis 
(18). Notably, Bcl-2 and Bcl-xL are dispensable for Treg survival, 
as demonstrated by the fact that FoxP3-specific deletion of Bcl-xL 
did not affect Treg survival (18).
This differential expression and dependency on Bcl-2 factors 
among lymphocyte subpopulations might be exploited as a novel 
target for immunotherapy. Particularly, small molecule inhibitors 
selectively targeting certain Bcl-2 family members might provide 
a novel pharmacological tool for immunomodulation through 
a selective depletion of lymphocyte subsets by apoptosis. The 
small molecule inhibitor ABT-737 binds Bcl-2, Bcl-xL, and 
Bcl-w proteins with high affinity, and Mcl-1 and A1 with much 
lower affinity (19). Thus, cell populations whose survival depends 
primarily on antiapoptotic Mcl-1 and/or A1 are resistant to ABT-
737-mediated apoptosis (20, 21). We hypothesized that survival 
of Tregs should not be affected by Bcl-2 and Bcl-xL inhibition and 
that the previously reported lymphotoxic effect of ABT-737 might 
spare the Treg compartment (22, 23).
MaTerials anD MeThODs
Mice
C57BL/6 (B6, H-2b), CBA (H-2k), BALB/c (H-2d), B6xCBAF1 
(H-2b/k), B6.Cg-FoxP3tm1Mal/J (FoxP3-GFP, H-2b), and B6-Tg(Fox 
P3-DTR/EGFP)23.3Spar (DEREG, H-2b) mice were housed under 
pathogen-free conditions at the University of Zürich and used 
for experiments at the age of 8–16 weeks, always in age- and sex-
matched groups. FoxP3-GFP mice express eGFP under the control 
of the FoxP3 transcription factor (24) and were kindly provided 
by Bernard Malissen (Centre d’Immunologie de Marseille-Luminy, 
France). With aging, these mice seem to express higher percentage 
of Tregs. For this reason, FoxP3-GFP mice were always perfectly 
age-matched within one experiment. DEREG mice express a 
FoxP3 BAC-driven primate diphtheria toxin (DT) receptor fused 
to eGFP, allowing to specifically depleting FoxP3+ cells with DT 
administration (25). DEREG mice were purchased from The 
Jackson Laboratory, and B6, CBA, BALB/c, and B6xCBA F1 mice 
were purchased from Harlan Laboratories. All animal experiments 
were performed according to protocols approved by the local legal 
authority (Veterinary office, Canton of Zürich, Switzerland).
Fluorescent-activated cell sorting
Fluorescent-activated cell sorting analyses were performed with 
a FACS Canto II or LSR II Fortessa (Becton Dickinson). The fol-
lowing antibodies were used to stain 1 × 106 cells of single cell 
suspensions of spleen or peripheral blood: CD4 (GK1.5) -PE, 
-APC, -AF700, CD8 (eBioH35.-17.2) -APC, B220 (RA3-6B2) 
-PE, CD25 (PC61.5) -PE/Cy7, -APC, F(ab’)2-FITC anti-rabbit 
IgG, FoxP3 (FJK-16s) -biotin, streptavidin–APC (all eBiosci-
ence), CD8 (53-6.7) -APC/Cy7 (all BioLegend), Mcl-1 (Y37), 
Bcl-2A1 (EP517Y) (both Abcam), Bcl-2 (3F11) -FITC (Becton 
Dickinson), and Bcl-xL (54H6) -Alexa488, Bim (polyclonal) 
(both Cell Signaling Technologies). For live-dead discrimination 
PI, 7-AAD or Zombie Aqua fixable viability kit (BioLegend) was 
used. Mice were bled sublingual and chimerism was analyzed in 
peripheral leukocytes at different time points after bone marrow 
transplantation (BMT), and donor-derived cells were identified 
by staining of donor H-2Kk. From the signal measured in a posi-
tive control (CBA), the background signal of a negative control 
(B6) was subtracted and converted to be 100%. The same formula 
was then used to calculate the percentage of donor-derived cells 
in mixed chimeras. For intracellular staining, a FoxP3-staining 
buffer set (eBioscience) was used according to the manufacturer’s 
instructions.
aBT-737 sensitivity In Vitro
For in  vitro experiments, ABT-737 (AbbVie Bioresearch) was 
dissolved in DMSO at a concentration of 5  mM and then 
further diluted in RPMI medium containing 10% fetal bovine 
serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μM 
2-mercaptoethanol. Either freshly isolated, in vitro IL-2- (R&D 
Systems, PeproTech) stimulated (3  days with 100  U/ml) or 
alloantigen-stimulated FoxP3-GFP splenocytes (see iTregs 
below) were plated in 96-well plates in culture medium at 
a concentration of 2.5  ×  106  cells/ml. Different amounts of 
ABT-737 or DMSO vehicle control were added to cells and 
incubated for 12 h at 37°C and 5% CO2. Cells were washed 3×, 
stained, and viability of CD4+(CD25+)GFP+ and CD4+(CD25−)
GFP− cell populations was assessed by PI or 7-AAD exclusion. 
Absolute cell counts per well were determined by the addition of 
absolute counting beads (Invitrogen). Surviving cell numbers of 
each population were normalized to the corresponding vehicle 
condition.
In Vitro antigenic Treg stimulation
For Treg activation, mixed lymphocyte reactions (MLRs) were 
performed in 24-well plates. CBA splenocytes (stimulators) 
were depleted of T cells (CD3 microbeads), and FoxP3-GFP 
splenocytes (responders) were depleted of CD25+ cells by 
automatic magnetic cell separation according to manufacturer’s 
instructions (Miltenyi Biotec) and then plated at a 1:1 ratio at a 
concentration of 4 × 106 cells/ml. Anti-CD154 antibody (50 μg/
ml, MR1, Bio-X-cell) was added and cells were incubated at 
37°C and 5% CO2. After 24 h of stimulation, 5 ng/ml TGF-β1 
(R&D Systems, PeproTech) and 100 U/ml IL-2 were added to the 
cultures. After another 72 h of stimulation, all cells were pooled 
and plated in 96-well plates in order to test ABT-737 sensitivity 
(see above).
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In Vivo antibody and Drug Treatments
Antibodies against CD154 (MR1), CD25 (PC61.5) (Bio-X-cell), 
and GITR [DTA-1, provided by Sakaguchi (26)] were diluted in 
PBS and injected i.p. as described below. DT (1 μg, Calbiochem) 
was administered by i.p. injection on two consecutive days (27). 
For in vivo application, ABT-737 was dissolved in polyethylene 
glycol, Tween 80, DMSO, and dextrose solution, and injected 
i.p. at 50  mg/kg. CsA (Enzo Life Sciences) was dissolved in a 
Cremaphor EL/ethanol solution, then diluted in HBSS, and 
injected s.c. at 10  mg/kg. Control mice were treated with the 
corresponding vehicles.
short- and long-Term aBT-737 Treatment
For short-term ABT-737 treatment, mice received five ABT-737 
injections from days −3 to −1, before their spleens were harvested 
and analyzed on day 0. For long-term ABT-737 treatment, mice 
received injections for 4  weeks every other day and were bled 
sublingual on days 0, 7, 14, 21, and 28.
skin grafting
In all skin graft experiments, B6 or DEREG mice were recipients, 
CBA mice were donors, and BALB/c mice were third party controls. 
CBA and BALB/c are fully MHC-mismatched to B6/DEREG and 
among each other. For skin transplantations, recipient mice were 
anesthetized with ketamine/xylazine, pain treated with carprofen 
(NSAID), and shaved. Full thickness tail skin (about 1 cm2) of donors 
and third party controls was grafted to the back and considered 
rejected, when <10% of the graft remained viable (non-blinded).
Donor-specific Transfusion
In the donor-specific transfusion (DST) experiment, recipient 
mice were treated with a total of five injections of ABT-737/
vehicle on days −3 to −1, and anti-CD154 antibodies on days 0, 
6, 11, and 14 (0.25 mg each). On day 0, recipients received 1 × 107 
donor splenocytes in Media 199 containing 10  mM HEPES, 
10 μg/ml DNAse, and 4 μg/ml gentamycin by tail vein injection. 
B6 recipients received anti-GITR (4  mg) antibodies on day 6, 
DEREG recipients DT on day 6/7, and skin was grafted on day 7.
Bone Marrow Transplantation
The ABT-737 tolerance protocol was described in detail previ-
ously (28). The conditioning of mice consisted of ABT-737 and 
CsA treatment with a total of five injections on days −3 to −1, 
and one daily injection until day 11. Anti-CD154 antibodies 
(2 mg) were administered once 6 h before the transplantation of 
25 × 106 donor BM cells by tail vein injection on day 0 (in the 
same medium as described above for DST). Tregs were depleted 
with anti-CD25 antibodies (1.25 mg) or blocked with anti-GITR 
antibodies (4 mg) on day −1. Peripheral blood chimerism was 
monitored and 8 weeks after BMT all mice received skin grafts.
graft-Versus-host Disease
On day 0, B6xCBA F1 recipient mice were lethally irradiated 
(900 cGy) with a Cs source. Six hours later, mice were transplanted 
with 1 × 107 DEREG BM cells and 2 × 107 DEREG splenocytes 
by tail vein injection (in the same medium as described above 
for DST), which corresponded to 5.7  ×  106 T cells in total. 
Furthermore, mice received cefazolin (antibiotic, 1  mg) after 
transplantation on days 0 and 2. ABT-737 and/or CsA treatment 
started on day −1 and was continued until day 10, and following 
doses were injected: day −1: 75 mg/kg ABT-737 and 15 mg/kg 
CsA; day 0: 100 mg/kg ABT-737 and 15 mg/kg CsA; days 1–3: 
50 mg/kg ABT-737 and 10 mg/kg CsA; and days 4–10: 25–50 mg/
kg ABT-737 (mostly 35 mg/kg) and 10 mg/ml CsA. Thereafter, 
mice continued to receive 10 mg/kg CsA until death. In the initial 
phase after irradiation and T cell transfer, some of the already 
weakened animals did not well tolerate ABT-737 treatment 
and about 25% of animals died during the first few days after 
transplantation. Accordingly, ABT-737 dose was adjusted to the 
condition of individual animals. Tregs were depleted on day 14/15 
by DT administration. Mice were monitored daily and severity 
of GVHD was assessed non-blinded by a score consisting of (a) 
posture/activity, (b) fur texture, (c) skin integrity, and (d) body 
weight loss, as previously described in Ref. (29).
In Vivo Mixed lymphocyte reaction
For the “in  vivo MLR” experiment, F1 (B6xCBAF1) recipient 
mice received anti-CD154 antibodies (2 mg) 6 h before tail vein 
injection of 30 × 106 B6.FoxP3-GFP splenocytes (in the medium 
as described above for DST). The following 3 days mice received 
one daily injection of ABT-737/vehicle and CsA. Spleens were 
harvested and analyzed on day 4.
hemisplenectomy
For hemisplenectomy, mice were anesthetized by isoflurane 
inhalation, pain treated with buprenorphine, and treated with 
cefazolin (antibiotic). The abdomen was opened by midline inci-
sion, and two ligations were placed around the inferior vascular 
pedicle and the middle of the spleen, before half of the spleen was 
removed inferior to the intrasplenic ligation. The abdominal wall 
was closed with continuous suture.
statistics
Statistical analysis was performed with GraphPad Prism software. 
Unpaired two-tailed Student’s t-test was used to assess statistical 
differences between groups. IC50 values were calculated using a 
log(inhibitor) vs. (normalized) response model (variable slope) 
for in vitro ABT-737 sensitivity analysis. Survival in Kaplan–Meier 
survival curves was compared using log-rank test. In animal 
experiments, each data point represents results from one single 
mouse, whereas in in vitro experiments, one data point represents 
the mean of technical replicates (usually triplicates). P < 0.05 was 
considered significant, *P < 0.05; **P < 0.01; ***P < 0.001, and 
n.s., not significant.
resUlTs
Bcl-2/Bcl-xl inhibition results in relative 
Treg enrichment
To investigate the proapoptotic effect of ABT-737 on different 
lymphocyte subpopulations, we assessed cell viability after 
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overnight incubation of freshly isolated splenocytes with ABT-
737 in vitro. Tregs displayed a consistent survival advantage over 
Tcons, as reflected in a 13.2× higher IC50 value (Figure  1A). 
As a result, ABT-737 treatment led to a relative enrichment of 
Tregs in vitro (from 14.5 to 29.7% Tregs among CD4+ cells with 
increasing ABT-737 concentrations, Figure 1B). This resistance 
is consistent with the fact that the ABT-737 resistance factor 
Mcl-1 is of predominant importance for Treg survival (18). 
Comparison of the protein expression levels of the various antia-
poptotic Bcl-2 family members and proapoptotic Bim showed 
very similar expression of all factors among FoxP3+CD25+ Treg 
and FoxP3−CD25− Tcon populations, with the only exception of 
Bcl-xL (Figure S1 in Supplementary Material). After stimulation 
with IL-2, the resistance of Tregs increased further (approx. 
3300× higher IC50 value than Tcon), leading to a Treg enrichment 
up to 47% (Figures 1C,D). This increased resistance to ABT-737 
correlated to a strong upregulation of Mcl-1 under the effect of 
IL-2 (Figures 1E,F).
The relative resistance of Tregs to the proapoptotic effect of 
ABT-737 was confirmed in vivo. Naïve mice were treated for 
3 days with a total of five injections of ABT-737. This resulted 
in moderate lymphopenia as reflected in a reduced number of 
CD4+FoxP3− Tcons in the spleen. Absolute Treg numbers were 
also reduced upon ABT-737 treatment, but to a lesser extent 
than Tcon (Figure 1G) (22, 23). Thus, Bcl-2/Bcl-xL inhibition 
led to a significant higher percentage of Tregs among CD4+ 
cells in comparison to vehicle controls (Figures 1H,I). To fol-
low the enrichment of FoxP3+ cells among CD4 T cells in the 
spleen of the same mouse, hemisplenectomy was performed 
after 3  days of ABT-737 treatment. A 1.53-fold enrichment 
of Tregs compared to vehicle-treated animals was observed. 
FACS analysis of the remaining half of the spleen 10 days later 
showed equal percentage of FoxP3+ cells in the two groups; 
thus, Treg enrichment was rapidly reversed after therapy 
discontinuation (Figure  1J). Furthermore, we observed that 
this enrichment was transient also under continuous treat-
ment with ABT-737, with a peak at day 14 and with a return to 
baseline levels after 28 days (Figure 1K). Thus, Bcl-2/Bcl-xL 
inhibition resulted in a relative, temporary enrichment of 
Tregs in vitro and in vivo.
antigen-stimulated Tregs are resistant to 
Bcl-2/Bcl-xl inhibition
Blockade of the CD40-CD154 costimulatory pathway is a widely 
used approach in experimental tolerance protocols, and these 
protocols often promote Treg expansion and depend on their 
suppressive activity (30–32). Thus, we wished to investigate the 
impact of selective Bcl-2/Bcl-xL inhibition on survival of Tregs 
under such conditions of concomitant antigenic stimulation and 
anti-CD154 blockade. We stimulated Tregs in vitro from CD25-
depleted naïve splenocytes with allogeneic cells in the presence 
of CD154 blocking antibody (MR1) and TGF-β/IL-2 cytokines. 
ABT-737 incubation revealed high resistance of alloantigen-
activated Tregs, similar to the previously observed resistance of 
activated CD25+ Tcons (IC50 value 36,000× higher than in CD25− 
Tcons) (Figure 1L) (21).
To investigate the properties of activated Tregs in vivo, we took 
advantage of an “in vivo MLR model.” B6.FoxP3-GFP splenocytes 
were transferred into F1 (B6xCBA) recipients under costimula-
tion blockade with anti-CD154 antibodies, followed by ABT-737 
or vehicle treatment for 3 days. Low-dose cyclosporine A (CsA) 
was combined with ABT-737 to prevent TCR–calcineurin–
NFAT1-dependent upregulation of Bcl-2A1 (A1) in Tcons and 
thus preventing resistance of Tcons upon antigenic stimulation 
(21). ABT-737 treatment resulted in moderate lymphopenia and 
in a 2.4-fold enrichment of donor-derived Tregs (Figure  1M). 
Taken together, antigen-stimulated Tregs were resistant to Bcl-2/
Bcl-xL inhibition and exposure to ABT-737 resulted in a shift 
of the balance between Tregs and Tcons in favor of the Treg 
compartment.
Treg-Dependent alleviation of gVhD upon 
aBT-737 Treatment
Regulatory T cells are recognized for alleviating the course of 
GVHD, and Treg therapy has been successfully tested in this 
condition (5). Therefore, for the first functional application of 
our concept, we aimed to investigate whether ABT-737 mediated 
Treg enrichment has a favorable impact on GVHD. Recipient 
F1 (B6xCBA) mice were lethally irradiated and reconstituted 
with allogenic B6.DEREG bone marrow and T cells. DEREG 
mice express a FoxP3-driven primate DT receptor, which allows 
selective Treg depletion by DT administration (25). Body weight 
and a GVHD score consisting of activity/posture, fur texture, 
skin integrity, and weight loss was assessed daily. Mice were 
either treated with combined ABT-737 and low-dose CsA or 
CsA alone, starting 1  day before cell transfer and continued 
for 10 days (Figure 2A). GVHD onset was about 10 days after 
transplantation in control mice treated only with CsA, and the 
disease progressed to lethality within 3 weeks (Figures 2B–D). 
ABT-737 treated animals presented a markedly attenuated 
course of GVHD. Due to the severity of the disease, mice were 
not bled in order to directly show relative enrichment of Tegs 
upon ABT-737 treatment in this setting. However, Tregs were 
integral in mediating the positive effects of treatment, as Treg 
depletion at day 14 after transplantation induced a rapid onset of 
GVHD [median survival time (MST) 49.5 vs. 25.5 days in Treg 
depleted group, P < 0.001]. None of the ABT-737 treated animals 
developed skin lesions, and thus, they did not reach the maximal 
GVHD score. In conclusion, ABT-737 substantially attenuated 
GVHD across full MHC barriers and this effect was mediated 
by Tregs.
aBT-737 Treatment leads to Treg-Mediated 
Donor-specific hyporesponsiveness
To investigate whether this immunomodulatory effect was 
antigen-specific, we took advantage of an established model of 
full MHC-mismatched skin transplantation after DST under 
costimulation blockade (33). B6 or B6.DEREG-recipient mice 
received donor-type splenocytes (CBA) under the effect of anti-
CD154 antibody (Figure  3A). This induction therapy leads to 
deletion/anergy of donor-specific Tcons, favors the generation of 
FigUre 1 | naïve and activated Tregs are resistant to Bcl-2/Bcl-xl blockade.  
(Continued)
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FigUre 2 | aBT-737 treatment alleviates gVhD in a Treg-dependent manner. (a) Experimental setup for GVHD experiment: F1 (B6xCBA) mice received 
DEREG bone marrow cells and T cells after lethal irradiation on day 0 and treatment from day −1 until day 10 with ABT-737 and CsA (blue and green) or CsA only 
(white) until death. Tregs were depleted by DT administration on day 14/15 (blue). (B) GVHD score, (c) body weight loss, and (D) survival, n = 6–8/group. All data 
represent mean ± SEM, difference between treatment groups was assessed with a log-rank test. Data from one out of two independent experiments are shown.
(a,B) Freshly isolated FoxP3-GFP splenocytes or (c,D) after 3 days of IL-2 stimulation were used for in vitro experiments. (a,c) Cells were incubated for 12 h with 
the indicated concentrations of ABT-737. The number of viable CD4+FoxP3+ (black) and CD4+FoxP3− (white) cells per well was assessed by FACS and normalized 
to corresponding vehicle controls. Curve represents a log(inhibitor) vs. normalized response curve. (B,D) The percentages of FoxP3+ cells among CD4+ cells were 
assessed after 12h ABT-737/vehicle incubation. In vitro titration experiments were performed two to four times, representative experiments are shown.  
(e) Quantification of median expression of Mcl-1 in fresh and IL-2 stimulated (3 days) CD4+CD25+FoxP3+ splenocytes. (F) Representative FACS plot showing Mcl-1 
expression in Tregs (gray) and Tcons (white) upon IL-2 stimulation in same experiment. (g–i) FoxP3-GFP mice were treated with vehicle or ABT-737 i.p. for 3 days 
prior to harvesting. (g) Total counts of CD4+FoxP3− and CD4+FoxP3+ cells per spleen are shown. The ratio corresponds to CD4+ FoxP3+/FoxP3− of total cell counts 
in vehicle and ABT-737 treated animals. (h) The percentage of FoxP3+ cells among CD4+ cells. Pooled data of three independent experiments, n = 12/group.  
(i) Representative FACS plots of viable CD4+ splenocytes in vehicle and ABT-737 treated animals. (J) Mice were treated for 3 days with ABT-737 or vehicle and the 
next day hemisplenectomized for analysis of half spleen, 10 days later the other half spleen was analyzed. The percentage of FoxP3+ cells among CD4+ population 
upon ABT-737 treatment was normalized to vehicle-treated mice, n = 3/group. (K) Percentage of FoxP3+ cells among peripheral blood CD4+ cells during 4-week 
ABT-737 treatment, n = 4. (l) Tregs were activated in a mixed lymphocyte reaction with CD25-depleted B6.FoxP3-GFP responders, CD3-depleted CBA 
stimulators, and anti-CD154 antibodies for 24 h, and additional IL-2/TGF-β for 3 days. After 12 h incubation with ABT-737 or vehicle, viable cell counts were 
assessed by FACS and normalized to corresponding vehicle controls. Curve represents a log(inhibitor) vs. response curve. Representative FACS plot of cells after 
stimulation. One of two independent experiments is shown. (M) B6.FoxP3-GFP splenocytes were transferred to F1 (B6xCBA) recipients under anti-CD154 
costimulation blockade and treated with ABT-737 or vehicle and CsA for 3 days. Spleens were analyzed on day 4 by FACS. The percentage of transferred FoxP3+ 
cells among all CD4+ cells is shown. Pooled data of two independent experiments, n = 6/group. All data represent mean ± SEM, *P < 0.05, **P < 0.01, 
***P < 0.001, t-test was used to assess differences between treatment groups.
FigUre 1 | continued
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Tregs, and results in transient donor-specific hyporesponsiveness 
(34). We combined this protocol with a 3-day ABT-737 treatment 
prior to i.v. splenocyte injection. Seven days after DST, recipient 
mice received donor-type (CBA) and third party control (BALB/c) 
skin grafts. In this stringent strain combination, the original DST 
protocol (vehicle group) did not significantly prolong skin graft 
survival (Figure  3B). However, the short additional treatment 
with ABT-737 was sufficient to markedly prolong donor-type skin 
graft survival up to more than 100 days in some recipients (MST 
39/87 days for ABT-737 and 12/13 days for vehicle, Figures 3D,F). 
Notably, this effect was donor-specific and not due to generalized 
immunosuppression, as demonstrated by the only slightly delayed 
rejection of third party grafts. To assess the importance of Tregs 
in ABT-737-induced donor-specific hyporesponsiveness in this 
model, we depleted Tregs by DT injection in DEREG recipients or 
inhibited their function by GITR (glucocorticoid-induced TNFR 
family-related gene) ligation the day prior to skin transplantation 
(35). In absence of a functional Treg compartment, all skin grafts 
were rapidly rejected, and no difference between donor-type and 
third party grafts was observed (Figures 3C–G). Thus, although 
FigUre 3 | aBT-737 induces Treg-mediated donor-specific hyporesponsiveness. (a) Experimental setup for DST experiment: B6 or DEREG mice were 
treated with ABT-737 or vehicle for 3 days prior transfer of CBA splenocytes on day 0 and anti-CD154 antibody treatment on days 0, 6, 11, and 14. On day 7, mice 
received CBA (donor-type) and BALB/c (third party) skin grafts, and graft survival was monitored until rejection. (B) Survival of CBA (white) and BALB/c (black) grafts 
after vehicle treatment or (D,F) with ABT-737 treatment. (c,e) Tregs were blocked with anti-GITR antibodies the day prior skin grafting (day 6) in B6 recipients or  
(g) by DT injection (day 6/7) in DEREG recipients. n = 7/group, differences between treatment groups were assessed with log-rank test. (B–g) derived from 
independent experiments (data from two out of three independent experiments are shown).
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ABT-737 might have additional Treg-independent effects influ-
encing graft survival, we show here that the ABT-737-induced 
hyporesponsiveness was critically dependent on Tregs, and the 
transient alteration of the Treg/Tcon balance after ABT-737 treat-
ment was sufficient to create a strong tolerogenic milieu.
induction of Transplantation Tolerance by 
aBT-737 Depends on Tregs
A transient state of Treg-mediated donor-specific hyporespon-
siveness might represent an ideal environment to promote 
engraftment of allogeneic bone marrow cells. We previously 
FigUre 4 | Tolerance induction by aBT-737 requires Tregs. (a) Experimental setup of mixed chimerism tolerance protocol: B6 recipients were treated with five 
injections of ABT-737 and CsA during the 3 days prior transplantation of CBA bone marrow cells on day 0. Anti-CD154 antibodies were administered 6 h before 
bone marrow transplantation, and ABT-737/CsA treatment was continued until day 11 after transplantation. Tregs were blocked by anti-GITR antibodies (circles) or 
depleted by anti-CD25 antibody administration (squares) at day −1. Eight weeks after transplantation, mice received CBA donor-type (black) and BALB/c third party 
(white) skin grafts and survival of grafts was monitored until rejection. (B) Graft survival of control group and (c) of Treg blocked/depleted groups, n = 7/group.  
(D) Representative FACS plots of peripheral CD4+ cell chimerism in control mouse and Treg depleted mouse 2 months after bone marrow transplantation. Tolerance 
protocol shown in (B) was repeated several times and Treg blockade/depletion by anti-GITR and anti-CD25 once each.
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showed that a 2-week conditioning treatment with ABT-737, 
low-dose CsA, costimulation blockade (anti-CD154), and 
transplantation of 25 × 106 bone marrow cells resulted in stable 
mixed lymphohematopoietic chimerism and complete deletion 
of donor-reactive CD8+ cells in a fully MHC-mismatched strain 
combination (Figure 4A) (28). Grafting of donor-type (CBA) and 
third party control (BALB/c) skin grafts to B6 recipients 8 weeks 
later confirmed stable donor-specific immunological tolerance in 
most animals (Figure 4B). We hypothesized that ABT-737 medi-
ated Treg enrichment is a critical factor for tolerance induction in 
this myelosuppression-free protocol. To test this hypothesis, Tregs 
were either depleted with anti-CD25 antibody or functionally 
inhibited by GITR ligation the day prior to BMT. This antibody 
treatment indeed precluded the establishment of tolerance to 
skin grafts in all animals, because mixed chimerism induction 
was hampered in the absence of a functional Treg compartment 
(Figures 4C,D). Thus, the transient tolerogenic milieu caused by 
Treg enrichment through Bcl-2/Bcl-xL inhibition was required to 
induce mixed chimerism without myelosuppressive conditioning.
DiscUssiOn
A dysregulated balance between regulatory and effector cell 
populations is often involved in overshooting immune activation, 
such as in transplant rejection, autoimmunity, or allergies. Thus, 
the achievement of functional dominance of Tregs over Tcons is 
a major aim in a wide range of clinical conditions. Direct in vivo 
manipulation of the Treg/Tcon balance represents an alternative 
to Treg therapy in order to achieve Treg-mediated tolerance, and 
this can be achieved by the selective reduction or functional inhi-
bition of Tcons, while preserving the Treg population. To reach 
this goal, pathways that are differentially regulated among these 
two cell populations need to be identified and pharmacologically 
manipulated. For example, cellular metabolism reflected in dif-
ferential mTOR activity has been proposed to be such a pathway 
(36), and low-dose IL-2 administration selectively favored expan-
sion of Tregs (37).
In the present study, we propose the intrinsic apoptosis 
pathway as promising target to exploit the immunomodulatory 
potency of Tregs. On a functional level, antiapoptotic Mcl-1 is the 
predominant survival factor in Tregs, and loss of Mcl-1 results in 
drastic reduction of Treg numbers. In contrast, loss of Bcl-2 or 
Bcl-xL does neither result in a relative reduction of Treg numbers 
nor loss of function (18). Thus, the relative importance of Mcl-1 
and Bcl-2/Bcl-xL varies among Tregs and Tcons. According to a 
previous study, Tregs display a slightly differential expression pat-
tern in apoptosis-related genes than Tcons, which might account 
for differences in sensitivity to cytotoxic stress (38). There, the 
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biggest difference was found in Bcl-xL expression, a finding that 
we confirmed on protein level. Despite the facts that Bcl-xL is 
bound with high affinity by ABT-737 and at the same time seems 
to be redundant for Treg survival, it may confer resistance toward 
ABT-737-mediated apoptosis. In fact, it has been shown that 
increased Bcl-xL expression in lymphocytes confers resistance to 
ABT-737-mediated killing (39). In the present study, we phar-
macologically exploited these differences in the regulation of the 
intrinsic apoptosis pathway among Tregs and Tcons. Combined 
inhibition of antiapoptotic Bcl-2 and Bcl-xL induced a function-
ally important Treg enrichment in vivo. This concept was tested in 
very stringent immunological models: short-term Bcl-2/Bcl-xL 
inhibition was sufficient to substantially alleviate GVHD, to inhibit 
allogeneic immune responses against fully MHC-mismatched 
skin grafts and to allow bone marrow engraftment without myelo-
suppression in a mixed chimersm model. The tolerogenic effect 
of ABT-737 was only transient, but in combination with BMT, 
this approach allowed the induction of stable tolerance across 
full MHC barriers. Importantly, activated Tregs were even more 
resistant to ABT-737 than naïve Tregs, and these activated Tregs 
are presumably responsible for the donor-specificity observed in 
skin graft experiments. This fact offers the opportunity to generate 
an antigen-specific tolerogenic environment with broad clinical 
implication for immunomodulatory therapies. In transplantation 
medicine, donor-specific immunosuppression would represent 
an important step toward the prevention of rejection without the 
risks for infections and cancers.
Evasion of apoptosis is one of the hallmarks of cancer, as Bcl-2 
factors are often overexpressed in malignant cells. Thus, large 
efforts are taken for developing highly selective Bcl-2 family 
inhibitors. To date, little is known about apoptosis regulation in 
human T cell subsets. For clinical translation of the proposed 
immunomodulatory concept, closer research on human cells will 
be needed, but tailored Bcl-2 inhibition is likely to translate into 
clinical therapies. Several Bcl-2 inhibitors have already entered 
clinical trials for various cancers and recently, a phase I study 
with ABT-199 in systemic lupus erythematosus patients has been 
completed (40–42). Bcl-2 inhibitors showed a favorable toxicity 
profile so far. The present study might stimulate further research 
on the effect of these inhibitors on T cells subsets directly in 
patients and importantly, it might draw attention to potentially 
unwanted side-effects in cancer patients with regard to a tumor 
immunology point-of-view by changing the Treg/Tcon balance 
on the short-term.
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